SPRO — Spero Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $40.54m
- -$12.35m
- $47.98m
Annual income statement for Spero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 9.33 | 18.3 | 53.5 | 104 | 48 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 88.4 | 106 | 99.3 | 82.3 | 121 |
| Operating Profit | -79.1 | -88 | -45.8 | 21.5 | -73.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -78.3 | -89.8 | -46.4 | 25.4 | -68.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -78.3 | -89.8 | -46.4 | 22.8 | -68.6 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -78.3 | -89.8 | -46.4 | 22.8 | -68.6 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -78.8 | -89.8 | -46.4 | 22.8 | -68.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.52 | -2.91 | -0.83 | 0.52 | -1.25 |